Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

2024年3月15日，尽管Novo Nordisk（NYSE:NVO）的II期肥胖试验结果不尽如人意，TD Cowen仍维持其买入评级和155.00美元的目标价。该试验研究了公司的CB1阻断剂monlunabant，在16周时显示约6-7%的体重减轻。 这次更新未能达到预期的疗效和安全性，但未发现严重的神经精神不良事件。然而，接受monlunabant治疗的参与者出现轻度至中度神经精神副作用的情况 ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Shares were down 4.3% at 1330 GMT, the lowest since August 8, after the company announced headline results from its trial of ...